Bathi sadurunge bunga, pajak, lan amortisasi: citiuspharma.com (CTXR)

EBITDA reflects Citius Pharmaceuticals' preparation for the independent market launch of its oncology drug via distribution networks. Simultaneously, the company is implementing protective mechanisms for catheters to minimize hospital-acquired infections. The 0.00 level is a current metric confirming its leadership status in the treatment of T-cell lymphomas, supported by Lymphir patents that create a robust barrier for competitors.

Citius Pharmaceuticals (CTXR) - Bathi operasional EBITDA saka 23.11.2025 nganti 10.11.2026

Ringkesan rincian data analitis Citius Pharmaceuticals, Inc. (CTXR)

- kuotasi lan prakiraan analis:

Bagan owah-owahan rega Citius Pharmaceuticals Inc.|CTXR - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Nilai pasar Citius Pharmaceuticals|CTXR - Nilai Total Perusahaan

- data kapitalisasi buku:

Ekuitas saben Saham Citius Pharmaceuticals|CTXR - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih citiuspharma.com|CTXR - Aset Agregat Perusahaan

- data tingkat utang lan likuiditas finansial:

Utang marang Modal Citius Pharmaceuticals|CTXR - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Citius Pharmaceuticals Inc.|CTXR - Utang perusahaan|Utang-utang marang nilai buku Citius Pharmaceuticals|CTXR - Utang jangka dawa perusahaan|Tanggungan jangka cendhak Citius Pharmaceuticals|Likuiditas darurat citiuspharma.com

- indikator bathi lan kelipatan valuasi:

CTXR - Penghasilan resik|Penghasilan resik sing dikarepake Citius Pharmaceuticals|CTXR - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Citius Pharmaceuticals Inc.|CTXR - Pangali PEG|Nilai bisnis marang bathi operasional sadurunge panyusutan Citius Pharmaceuticals|CTXR - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Citius Pharmaceuticals|CTXR - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan citiuspharma.com|CTXR - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Citius Pharmaceuticals

Analisis kabeh metrik perusahaan:Citius Pharmaceuticals

Produk asil prodhuksi Citius Pharmaceuticals Inc.

The fundamental attractiveness of the asset is determined by its ability to generate a sustainable cash flow, making the analysis of operational efficiency key to calculating valuation multiples. The EBITDA trend reflects the actual volume of earnings before interest, taxes, depreciation, and amortization, demonstrating the ability of Citius Pharmaceuticals (CTXR) to monetize innovative drugs through settlements with insurance companies and government healthcare systems.

Karo sapa Citius Pharmaceuticals saingan